A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy

Li, Fenge; Wang, Liping; Zhang, Yixiang; Feng, Weihong; Ju, Tao; Liu, Zaiping; Li, Xiqing; Du, Xueming

doi:10.3389/fonc.2021.640131

Cited by 6 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ethics review of Beichen Hospital was carried out in the form of in-person meetings, and the ethics certificate can be provided as needed. The inclusion criteria of the studied patients were as follows: (1) diagnosed with NSCLC by tumor core biopsy; (2) had not received any anti-tumor treatments including chemotherapy, radioactive therapy, and immunotherapy at the time of getting tumor biopsy; (3) tumor samples can be obtained after pathology diagnosis, and at least two slides of tumor tissues were available for the study; and (4) immediately after diagnosis, all patients received standard chemotherapy (Paclitaxel, 135–175 mg/m 2 and Cisplatin 75 mg/m 2 ) and 125 I brachytherapy (SNCP- 125 I) ( 23 ) until disease progression according to the NCCN clinical guidelines. Patients who did not meet the criteria mentioned above were excluded.…”

Section: Methodsmentioning

confidence: 99%

Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III/IV non-small-cell lung cancer

Li,

Tian,

Wang

et al. 2024

Front. Med.

Self Cite

View full text Add to dashboard Cite

Background and aimLymphocytes are effector cells that fight cancer by killing tumor cells. Here, we aim to explore the prognostic significance of both peripheral and tumor-infiltrating lymphocytes (TILs) in newly diagnosed stage III/IV non-small-cell lung cancer (NSCLC).Materials and methodsIn total, 105 cases of newly diagnosed stage III/IV NSCLC from July 2017 to October 2022 at the Tianjin Beichen Hospital were retrospectively investigated. Peripheral blood samples at the time of diagnosis and tumor tissue slices from these patients were collected. General peripheral blood cell composition and TILs were measured and analyzed via an automatic blood analyzer and immunofluorescence staining analysis. The overall survival (OS) time of all patients was also obtained and analyzed.ResultsThe median overall survival (mOS) of all patients is 12 months. The 1-, 2-, and 3-year overall survival rates were 60.5, 28.4, and 18.6%, respectively. Peripheral lymphocyte and neutrophil percentages, serum C-reactive protein (CRP) expression, tumor size, and tumor pathology are the prognostic factors of OS for newly diagnosed stage III/IV NSCLC patients. Moreover, patients with high tumor CD4+ and CD8+ T cell infiltration survived significantly longer compared to patients with low tumor CD4+ and CD8+ T cell infiltration (p < 0.0001 and p = 0.011, respectively). Compared to low tumor CD33+ cell infiltration, high tumor CD33+ cell infiltration was associated with worse OS (p = 0.018). High tumor CD8+ T cell infiltration was associated with lower peripheral lymphocyte number, lower serum CRP expression, smaller tumor size, and better tumor pathology (p = 0.012, p = 0.040, p = 0.012, and p = 0.029, respectively).ConclusionIncreased numbers of peripheral lymphocytes, CD33+ cells, CD4+ TILs, and CD8+ TILs were significantly associated with OS in newly diagnosed stage III/IV NSCLC patients, which were positively associated with several basic clinical factors.

show abstract

Section: Methodsmentioning

confidence: 99%

Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III/IV non-small-cell lung cancer

Li,

Tian,

Wang

et al. 2024

Front. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…These findings suggest that platelets may be crucial in the growth of tumors in a variety of cancer types. Platelet research is mostly focused on the relationship between platelet characteristics and the prognosis of malignant tumors[ 4 , 5 ]. It may be possible to find novel treatment targets and improve the prognosis of malignant tumors by better understanding platelet-related genes and the underlying processes.…”

Section: Introductionmentioning

confidence: 99%

Integrative analysis of platelet-related genes for the prognosis of esophageal cancer

Du¹,

Wang²,

Hu³

et al. 2022

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Every year, esophageal cancer is responsible for 509000 deaths and around 572000 new cases worldwide. Although esophageal cancer treatment options have advanced, patients still have a dismal 5-year survival rate. AIM To investigate the relationship between genes associated to platelets and the prognosis of esophageal cancer. METHODS We searched differentially expressed genes for changes between 151 tumor tissues and 653 normal, healthy tissues using the “limma” package. To develop a prediction model of platelet-related genes, a univariate Cox regression analysis and least absolute shrinkage and selection operator Cox regression analysis were carried out. Based on a median risk score, patients were divided into high-risk and low-risk categories. A nomogram was created to predict the 1-, 2-, and 3-year overall survival (OS) of esophageal cancer patients using four platelet-related gene signatures, TNM stages, and pathological type. Additionally, the concordance index, receiver operating characteristic curve, and calibration curve were used to validate the nomogram. RESULTS The prognosis of esophageal cancer was associated to APOOL , EP300 , PLA2G6 , and VAMP7 according to univariate Cox regression analysis and least absolute shrinkage and selection operator regression analysis. Patients with esophageal cancer at high risk had substantially shorter OS than those with cancer at low risk, according to a Kaplan-Meier analysis ( P < 0.05). TNM stage (hazard ratio: 2.187, 95% confidence interval: 1.242-3.852, P = 0.007) in both univariate and multivariate Cox regression and risk score were independently correlated with OS (hazard ratio: 2.451, 95% confidence interval: 1.599-3.756, P < 0.001). CONCLUSION A survival risk score model and independent prognostic variables for esophageal cancer have been developed using APOOL , EP300 , PLA2G6 , and VAMP7 . OS for esophageal cancer might be predicted using the nomogram based on TNM stage, pathological type, and risk score. The nomogram demonstrated strong predictive ability, as shown by the concordance index, receiver operating characteristic curve, and calibration curve.

show abstract

“…In a recent retrospective study, Li et al. ( 2 ) developed a single needle cone puncture method for 125 I seed (SNCP- 125 I) brachytherapy for the treatment of thoracic malignancy. The study is especially of great significance in the treatment of patients with lung hilar and mediastinal tumors, which offers an extremely effective therapeutic approach.…”

mentioning

confidence: 99%

Commentary: A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy

et al. 2022

View full text Add to dashboard Cite

A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy

Cited by 6 publications

References 40 publications

Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III/IV non-small-cell lung cancer

Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III/IV non-small-cell lung cancer

Integrative analysis of platelet-related genes for the prognosis of esophageal cancer

Commentary: A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy

Contact Info

Product

Resources

About